Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07455045) titled 'A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)' on March 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Condition:
High Grade Glioma (III or IV)
Diffuse Midline Glioma (DMG)
Glioblastoma (GBM)
Intervention:
Drug: FZ-AD005
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: March 1, 2026
Target Sample Size: 40
Countries of Recruitment:
China
To know more, visit https://cli...